[ad_1]
IBM Watson Health is phasing out its Drug Discovery program, which uses AI software to help companies develop new pharmaceuticals, with poor sales.
However, the service does not stop completely. Spokesperson of IBM Ed Barbini said The register"We will not interrupt our Watson for Drug Discovery offering and remain committed to the continued success of our customers who are currently using this technology. At Watson Health, we focus our resources on parallel clinical development, where we see an even greater market need for our data and AI capabilities. "
In other words, it seems that the product will not be sold to new customers. However, organizations that wish to continue using the system will still be supported. When we asked Blue Blue manufacturers to clarify this, they tried to minimize the situation by using these supposedly generated words from Watson's neural network:
The bad cup of Java leaves an unpleasant taste in the mouth "AI" IBM Watson: Five security bugs to splash into an badyzer
READ MORE
IBM is abandoning its efforts to develop and denature its Drug Discovery technology because of "sluggish sales," according to the medical news bulletin Stat, which reported the case for the first time.
The Drug Discovery service consists of many different products or "modules", such as a search engine that allows chemists to explore scientific summaries to find information about a specific gene or chemical compound. There is also a network of knowledge describing the relationships between drugs and diseases.
IBM's health division has been collapsing for some time. Last year, he fired a large portion of his employees after failing to secure hospital contracts. The failure was apparently caused by internal competition and workplace dramas.
Its technology is not irreproachable either. IBM Watson Health artificial intelligence software for artificial intelligence has issued incorrect and dangerous recommendations for doctors trying to treat cancer. To top it off, Deborah DiSanzo, director of Watson Health at IBM, also left. ®
Sponsored:
Become a leader in pragmatic security
Source link
